<DOC>
	<DOCNO>NCT00041782</DOCNO>
	<brief_summary>Study Plan : Adult cancer patient low risk profile present DVT receive dalteparin 200 IU/kg subcutaneously daily ( base actual body weight maximum dose 18,000 IU ) . Eligible patient sign informed consent instruct injection technique , give first subcutaneous injection supervision physician nurse observe minimum 1-2 hour prior discharge . Patients may admit observation unit 24 hour prior discharge medically necessary . Those patient without complication observation period give discharge instruction outpatient schedule see one physician investigator daily subcutaneous injection dalteparin , routine lab work initiation oral anticoagulation therapy . Patients proficient administer injection dalteparin evaluate every day physician investigator . On day home injection , study nurse call patient check patient 's status remind patient his/her daily injection . Patients undergo physical examination every day physician investigator direct towards clinically affect area therapeutic response ( INR 2-3 ) oral warfarin achieve patient 's clinical condition warrant modification therapy without hospitalization . Patients remain study minimum 5 day least 1 day therapeutic oral anticoagulation . The quality life patient enrol assessed use Modified Medical Outcome Study Short Form-20 . An adapted version Rotterdam Symptom Checklist use specifically assess patient thrombosis . Patients complete two instrument study entry , day 3 , day 5 end study different day 5 .</brief_summary>
	<brief_title>Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin ( Fragmin ) In Low Risk Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Inclusion Criteria Cancer patient document DVT meeting eligibility criterion enter study consent participate . Patients eligible study include : Patients solid tumor ( include lymphoma myeloma ) . Patients clinical venographic ultrasonographic evidence thrombosis proximal distal low upper extremity . Patients catheterrelated thrombosis eligible study candidate thrombolytic therapy . Patients Zubrod performance status &lt; 2 . ( Appendix A ) Patients adequate bone marrow function : platelet &gt; 100,000/mm3 , ANC &gt; 1,500 cells/mm3 . Patients adequate renal function : creatinine &lt; 2.5 mg/dL . Patients adequate liver function : SGPT &lt; 1.5 x upper limit normal , alkaline phosphatase &lt; 2.5 x upper limit normal , bilirubin &lt; 1.5 mg/dL . Patients must caregiver available willing assist care transportation first 72 hour study period . Patients must telephone within home . Patients must live stay within 30mile radius study site . Patients must history compliance outpatient therapy followup visit . Patients must able read complete study instrument . Exclusion Criteria A patient must enrol criterion apply : Prior history DVT PE past year . Evidence active bleeding , active peptic ulcer disease , familial bleeding disorder proven diagnostic study . A Hemoglobin 7.5 less . Concurrent symptomatic PE past year . Currently receive treatment UFH DVT . An inability treat LMWH outpatient comorbidities clinical condition require hospitalization : ( cerebral vascular accident , uncontrolled diabetes mellitus , uncontrolled hypertension , new onset atrial fibrillation , chronic obstructive pulmonary disease dyspnea , / trauma ) . Hypotension ( systolic blood pressure &lt; 90 mm Hg ) . Tachypnea ( respiratory rate &gt; 30/min. ) . Altered sensorium . Uncontrolled hypercalcemia ( Corrected calcium &gt; 12mg/dL ) . Hyponatremia ( serum sodium &lt; 128 mg/dL ) . Women pregnant nursing . Expected decrease platelet count le 50,000 next 10 day follow entry . Patients presence know deficiency antithrombin III , protein C , protein S. Patients known history activate protein C resistance . Patients oral anticoagulant ( anisindione , dicumarol warfarin ) and/or platelet inhibitor ( aspirin , abciximab , alprostadil , dipyridamole , sulfinpyrazone , ticlopidine NSAIDS ) could affect hemostasis . Patients previous heparininduced thrombocytopenia . Patients epidural catheter . Patients hypersensitivity reaction UFH , dalteparin porcine product . Patients know noncompliance previous treatment regimen . Patients primary central nervous system tumor , brain metastasis evidence leptomeningeal disease . Treatment Plan ( Appendix B )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Deep Vein Thrombosis</keyword>
</DOC>